Plain-English translation of NCT07587515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a Phase 1b/2a study testing a new treatment called for wet age-related macular degeneration (AMD), an eye disease that can cause vision loss in older adults. The medication is given as an injection directly into the eye once every 24 weeks. Researchers want to learn whether this treatment is safe, how your body responds to it, and whether it can help slow or stop vision loss from this condition.
Current treatments for wet AMD require frequent eye injections (often every 4 to 8 weeks), which can be burdensome for patients. This new medication is being tested to see if it can work effectively with much less frequent injections—potentially only four times a year—while remaining safe and effective.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the study medication into your eye four times over approximately two years (every 24 weeks). At each visit, you'll have eye exams and imaging tests to monitor how well the treatment is working and check for any side effects. The study team will also monitor how your body handles the medication and watch for any immune responses to it.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States